Hyperphosphatemic Familial Tumoral Calcinosis: Disease-Characteristics Report

Executive summary

Hyperphosphatemic familial tumoral calcinosis (HFTC) is an ultra-rare Mendelian disorder caused by deficient fibroblast growth factor-23 (FGF23) activity. Biallelic pathogenic variants in GALNT3, FGF23, or KL cause renal phosphate retention, hyperphosphatemia, inadequately suppressed calcitriol, and deposition of calcium-phosphate material in periarticular and other soft tissues. Hyperostosis-hyperphosphatemia syndrome (HHS) is now considered part of the same phenotypic spectrum. Clinical expression ranges from biochemical-only disease to recurrent inflammatory hyperostosis, massive disabling calcific tumors, dental abnormalities, and vascular or visceral calcification. Evidence remains limited principally to case reports, small cohorts, and animal models; no disease-specific randomized treatment trial or validated management guideline was identified. (ramnitz2016phenotypicandgenotypic pages 1-6, ito2021congenitalhyperphosphatemicconditions pages 1-2)

Table: Concise evidence table covering HFTC classification, genetics, biochemical and clinical phenotypes, diagnosis, management, epidemiology, and experimental models. Quantitative findings are separated from suggested ontology mappings, with uncertain mappings explicitly flagged for verification.

1. Disease information

Definition and classification

HFTC is a rare disorder of FGF23 deficiency or resistance characterized by persistent hyperphosphatemia, excessive renal tubular phosphate reabsorption, elevated or inappropriately normal 1,25-dihydroxyvitamin D [1,25(OH)₂D], and ectopic calcification. “Tumoral” describes the mass-like appearance; the deposits are not neoplastic. HFTC and HHS overlap genetically and clinically: calcific masses predominate in HFTC, whereas recurrent painful diaphyseal hyperostosis may dominate in HHS. (ramnitz2016phenotypicandgenotypic pages 1-6, ito2021congenitalhyperphosphatemicconditions pages 3-4)

Identifiers and synonyms

• Familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome: Orphanet 306661.
• HFTC1, usually GALNT3 related: OMIM 211900.
• HFTC2, FGF23 related: OMIM 617993; MONDO:0060714.
• HFTC3, KL related: OMIM 617994; MONDO:0060715. (OpenTargets Search: Hyperphosphatemic familial tumoral calcinosis-FGF23,GALNT3,KL, ito2021congenitalhyperphosphatemicconditions pages 2-3)
• Common names: hyperphosphatemic familial tumoral calcinosis, familial tumoral calcinosis, hyperphosphatemic tumoral calcinosis, FTC/HHS, HFTC/HHS, and hyperostosis-hyperphosphatemia syndrome.
• A single umbrella MONDO identifier was not established in the retrieved evidence; subtype MONDO identifiers above are directly supported. A dedicated ICD-10/ICD-11 or MeSH code specific to inherited HFTC was likewise not verified; broader calcinosis or mineral-metabolism codes may be used clinically but are not disease-equivalent.

This report synthesizes aggregated disease-level literature, not individual EHR data. Patient-level observations are drawn from published consented cohorts and case reports.

2. Etiology, risk, and protective factors

Causal factors

HFTC is primarily genetic and autosomal recessive:

1. GALNT3 loss of function impairs O-glycosylation and stabilization of FGF23.
2. FGF23 loss of function impairs synthesis, secretion, stability, or bioactivity of the phosphaturic hormone.
3. KL loss of function impairs Klotho-dependent FGF23 receptor signaling, producing hormone resistance. (farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4, ito2021congenitalhyperphosphatemicconditions pages 1-2)

A rare acquired phenocopy caused by anti-FGF23 autoantibodies has been reported and should be considered when biochemical HFTC is present without biallelic variants in the three established genes. (ito2021congenitalhyperphosphatemicconditions pages 3-4)

Risk and modifying factors

• Genetic risk: two pathogenic alleles in one causal gene; consanguinity and an affected sibling substantially increase prior probability. In a literature review covering 64 cases through 2017, 44 involved GALNT3, 19 FGF23, and one KL, making GALNT3 the most frequently reported cause. (ito2021congenitalhyperphosphatemicconditions pages 2-3)
• Family history: may be absent because recessive carriers are usually asymptomatic and de novo presentations can occur through unrecognized carrier mating or unusual mechanisms.
• Environmental/lifestyle risk: no toxin, infection, smoking, alcohol, or occupational exposure causes inherited HFTC. High dietary phosphate plausibly aggravates hyperphosphatemia, but a quantified gene–diet effect has not been established.
• Tissue injury and comorbidity: local pressure or trauma may influence where masses become clinically apparent. A 2023 case proposed that limited scleroderma contributed to very late calcinosis, but this is a single-patient hypothesis rather than demonstrated causation. (iwasaki2023elderlyonsetcalcinosisof pages 6-6)
• Protective factors: no validated protective allele is known. Dietary phosphate restriction and early biochemical control are therapeutic or tertiary-preventive measures, not proven protection against inheriting or developing the molecular disorder.
• Modifier genes/epigenetics: no replicated HFTC-specific modifier locus, methylation signature, or chromatin mechanism was identified. General epigenetic regulation of mineral metabolism should not be entered as HFTC-specific evidence.

3. Phenotypes

Core phenotype and suggested HPO annotations

The NIH cohort’s median 1,25(OH)₂D was 62 pg/mL and median calcium-phosphate product was 63.5 mg²/dL². Calcium, creatinine, and alkaline phosphatase were generally normal. (ramnitz2016phenotypicandgenotypic pages 6-10)

A dedicated dental cohort found pulp obliteration in 13/14 evaluable patients (93%); all ten comprehensively examined participants with GALNT3 variants had shortened thistle-shaped roots and pulp obliteration. Premolars were more severely affected than canines, molars, or incisors, and mean phosphate was 6.4 ± 1.0 mg/dL. (lee2021across‐sectionalcohort pages 4-5)

Onset, severity, progression, and quality of life

Onset ranges from infancy to late adulthood and severity varies even among relatives with the same genotype. Calcific masses are not generally present neonatally and tend to accrue with age; reported individual onset ages include 4 and 23 years. A 2023 genetically confirmed case did not manifest clinically important calcinosis until the patient’s seventies. (chakhtoura2018hyperphosphatemicfamilialtumoral pages 1-2, ito2021congenitalhyperphosphatemicconditions pages 3-4, iwasaki2023elderlyonsetcalcinosisof pages 6-6)

Periarticular masses cause pain, reduced range of motion, impaired walking and self-care, ulceration, infection risk, and repeated surgery. Inflammatory attacks cause severe limb pain and constitutional illness. No validated HFTC-specific EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life dataset was identified.

4. Genetic and molecular information

Causal genes

• GALNT3 encodes polypeptide N-acetylgalactosaminyltransferase-3, a trans-Golgi glycosyltransferase. It O-glycosylates FGF23 near Thr178 and protects the Arg179–Ser180 cleavage region.
• FGF23 encodes the 251-amino-acid precursor of a bone-derived phosphaturic hormone; after signal-peptide removal, the secreted product contains 227 amino acids.
• KL encodes α-Klotho, the obligate coreceptor that permits high-affinity FGF23 signaling through principally FGFR1c in kidney. (farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4, ito2021congenitalhyperphosphatemicconditions pages 1-2)

Open Targets independently supports disease associations for GALNT3, FGF23, and KL, linked to primary literature including PMID 15133511 for GALNT3, PMIDs 15590700 and 16151858 for FGF23, and PMID 17710231 for KL. (OpenTargets Search: Hyperphosphatemic familial tumoral calcinosis-FGF23,GALNT3,KL)

Pathogenic variants

Reported germline variants include missense, nonsense, frameshift, splice-site, and small insertion/deletion alleles. FGF23 examples include p.His41Gln, p.Gln54Lys, p.Ser71Gly, p.Met96Thr, p.Gly123Trp, p.Ser129Pro, and p.Ser129Phe; the established KL example is p.His193Arg. The FGF23 p.Ser71Gly mutant can be retained in the Golgi, with preferential secretion of C-terminal fragments. (ito2021congenitalhyperphosphatemicconditions pages 3-4, farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4)

Recent examples include homozygous GALNT3 c.1524+1G>A in three siblings reported in 2024 and a novel late frameshift in the lectin domain reported in an elderly patient in 2023. These examples broaden variant and age-of-presentation spectra but do not establish new genes or treatment standards. (iwasaki2023elderlyonsetcalcinosisof pages 6-6, alghubishi2024type1hyperphosphatemic pages 5-5)

Variants are constitutional/germline, not somatic drivers. Most disease alleles are functionally loss-of-function. Population allele frequencies must be retrieved variant-by-variant from a current gnomAD release; the evidence set does not support assigning a universal frequency. Likewise, each variant requires contemporary ACMG/AMP classification using ClinVar, segregation, population, and functional data rather than assuming pathogenicity from gene membership.

No recurrent chromosomal abnormality is established. Uniparental disomy can theoretically unmask a recessive GALNT3 allele, but CMA, karyotyping, and FISH are not routine first-line tests. No HFTC-specific epigenetic biomarker is validated.

5. Environmental information

There is no evidence that pollution, radiation, occupational toxins, smoking, alcohol, or an infectious organism initiates familial HFTC. Dietary phosphate influences the biochemical substrate burden and is therefore clinically actionable. Local mechanical stress may help explain periarticular localization, while tissue injury, ulceration, and secondary infection can worsen established lesions. Rheumatologic comorbidity as a modifier is currently supported only by isolated observation. (cherian2024clinicalcharacteristicstherapeutic pages 2-3, iwasaki2023elderlyonsetcalcinosisof pages 6-6)

6. Mechanism and pathophysiology

Ordered causal chain

1. Biallelic GALNT3 or FGF23 loss-of-function variants lead to deficient secretion or excessive proteolytic cleavage of intact bioactive FGF23; alternatively, biallelic KL variants lead to resistance to intact FGF23. (farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4, ito2021congenitalhyperphosphatemicconditions pages 1-2)
2. Deficient FGF23–Klotho–FGFR1c signaling leads to inadequate downregulation of renal proximal-tubular sodium-phosphate cotransporters NaPi-IIa/NaPi-IIc.
3. Persistent transporter activity leads to excessive tubular phosphate reabsorption and hyperphosphatemia.
4. Loss of FGF23 action also leads to failure to suppress renal calcitriol production, resulting in elevated or inappropriately normal 1,25(OH)₂D.
5. Calcitriol activity leads to increased intestinal calcium and phosphate absorption, further increasing the calcium-phosphate product.
6. High extracellular phosphate and calcium-phosphate product lead to precipitation of calcium-phosphate material in periarticular soft tissue, vessels, dental pulp, and viscera; the exact site-selection mechanism remains partly inferred. (ito2021congenitalhyperphosphatemicconditions pages 3-4, farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4)
7. Crystal deposition and tissue injury lead to macrophage-rich foreign-body inflammation, chronic inflammation, and sometimes heterotopic ossification.
8. Mass effect and inflammation lead to pain, ulceration, reduced joint movement, infection risk, and tissue or joint destruction. Independently, abnormal skeletal phosphate/FGF23 biology leads to episodic diaphyseal cortical hyperostosis and pain. (ramnitz2016phenotypicandgenotypic pages 13-17, ramnitz2016phenotypicandgenotypic pages 1-6)

Cellular and ontology annotations

Upstream cell types include osteocytes/osteoblast-lineage cells producing FGF23 (CL: osteocyte and osteoblast terms should be ontology-verified) and renal proximal-tubule epithelial cells responding through Klotho–FGFR signaling. Downstream lesions contain connective-tissue cells, macrophages, foreign-body giant cells, and in some cases osteoblast-like cells forming heterotopic bone.

Suggested GO concepts include phosphate-ion homeostasis (GO:0055062), inflammatory response (GO:0006954), hormone-mediated signaling, renal phosphate excretion, O-linked glycosylation, and biomineral tissue development (GO:0031214). Relevant compartments include the trans-Golgi network for GalNAc-T3 and the plasma membrane receptor complex for Klotho/FGFR1c; exact GO cellular-component identifiers should be verified before production use.

Histology in four NIH subjects showed ectopic calcification with chronic inflammation, and one showed mature lamellar heterotopic bone. Foamy macrophages and chronic inflammatory cells support a downstream innate immune response rather than primary autoimmunity in genetic HFTC. (ramnitz2016phenotypicandgenotypic pages 13-17, ramnitz2016phenotypicandgenotypic pages 1-6)

No reproducible HFTC-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or integrated multi-omics signature was identified. This is a major research gap.

7. Anatomical structures affected

Primary sites are periarticular skin, subcutaneous tissue, fascia, tendons, and connective tissue near the hip, elbow, and shoulder; knees, hands, and feet also occur. Hyperostosis principally involves cortical diaphyses of long bones, especially tibiae. Dental disease involves root cementum, pulp, pulp cavity, and odontoblast architecture. (ito2021congenitalhyperphosphatemicconditions pages 3-4, lee2021across‐sectionalcohort pages 4-5)

Secondary or less frequent sites include coronary and other vessels, colonic submucosa, eye, and testis. One NIH subject had complete shoulder-joint destruction and another had ulnar growth-plate destruction. Two of five evaluated subjects had coronary Agatston scores above the 95th percentile, although age and conventional cardiovascular risks confounded attribution. Lesions may be unilateral, bilateral, multifocal, and asymmetric; no fixed lateralization exists. (ramnitz2016phenotypicandgenotypic pages 13-17)

Suggested UBERON mappings include skin, subcutaneous tissue, hip joint, elbow joint, shoulder joint, tibia, coronary artery, colon, eye, testis, tooth pulp, and growth plate. Exact UBERON accession numbers require terminology-service validation.

8. Temporal development

HFTC is genetically present from conception but often clinically silent in infancy. The course is chronic and lifelong, with variable, episodic inflammatory attacks and progressive or recurrent calcific masses. Patients may have biochemical disease before palpable lesions; in the NIH cohort, two siblings initially lacked physical calcinosis and one later developed an elbow lesion. (ramnitz2016phenotypicandgenotypic pages 6-10)

No formal stages exist. A practical course model is: (1) biochemical hyperphosphatemia; (2) early dental or episodic hyperostotic disease; (3) localized tumoral calcinosis; and (4) multifocal disabling, ulcerating, vascular, or visceral disease. This is a clinical framework, not a validated staging system.

Spontaneous regression is reported but unpredictable. Treatment-associated complete resolution of one mass occurred after 13 months in the NIH cohort. The ideal preventive window is probably before large deposits form, but prospective evidence proving that early phosphate control prevents lesions is absent. (ramnitz2016phenotypicandgenotypic pages 1-6)

9. Inheritance and population

Inheritance is autosomal recessive. For two heterozygous parents, each pregnancy conventionally has a 25% probability of an affected child, 50% of an unaffected carrier, and 25% of a noncarrier. Expressivity is markedly variable; penetrance of biochemical hyperphosphatemia appears high in biallelic disease, whereas penetrance and timing of tumoral calcinosis are incomplete and age dependent. Anticipation is not known. Germline mosaicism has not emerged as a characteristic mechanism.

No reliable prevalence, incidence, carrier frequency, sex ratio, or survival estimate exists. Sixty-four genetically characterized cases were summarized through 2017, underscoring extreme rarity rather than defining population prevalence. Reports are enriched in African and Middle Eastern families and consanguineous pedigrees, but HFTC occurs worldwide. (ito2021congenitalhyperphosphatemicconditions pages 1-2, ito2021congenitalhyperphosphatemicconditions pages 2-3)

10. Diagnostics

Recommended diagnostic workflow

1. Confirm persistent, age-adjusted fasting serum phosphate elevation.
2. Measure calcium, creatinine/eGFR, alkaline phosphatase, PTH, 25-hydroxyvitamin D, and 1,25(OH)₂D.
3. Calculate TRP and TmP/GFR from paired serum/urine phosphate and creatinine. HFTC shows inappropriate phosphate conservation despite normal kidney function.
4. Measure both intact FGF23 and C-terminal FGF23 where available. GALNT3/FGF23 disease generally produces low or inappropriately normal intact hormone with high C-terminal fragments; KL disease produces high intact FGF23 because of resistance. (farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4, ramnitz2016phenotypicandgenotypic pages 6-10)
5. Image symptomatic sites using plain radiography; CT best defines calcific burden and surgical anatomy, while MRI can characterize inflammation but may misleadingly resemble osteomyelitis.
6. Sequence GALNT3, FGF23, and KL, preferably using a mineral-metabolism/calcification panel with deletion–duplication analysis. WES or WGS is appropriate if panel testing is negative or phenotype is atypical.
7. If no causal genotype is found, consider anti-FGF23 autoantibodies and reassess acquired causes.

Biopsy is unnecessary for classic biochemistry and imaging but may be required if malignancy, infection, or another calcifying disorder cannot be excluded. Expected pathology is amorphous calcium-phosphate material with macrophages/giant cells, chronic inflammation, fibrosis, and sometimes heterotopic bone. (ramnitz2016phenotypicandgenotypic pages 13-17)

CMA, karyotyping, FISH, mitochondrial sequencing, repeat-expansion testing, liquid biopsy, and routine diagnostic omics have no established role. Cascade biochemical and targeted genetic testing is appropriate for relatives; population or newborn screening is not established.

Differential diagnosis

Important alternatives are chronic kidney disease with secondary tumoral calcinosis, hyperparathyroidism, excess phosphate administration, vitamin-D intoxication, pseudohypoparathyroidism, dystrophic calcification from connective-tissue disease, calcinosis universalis, calcific tendinopathy, synovial osteochondromatosis, gout, malignancy, bacterial osteomyelitis, and chronic recurrent multifocal osteomyelitis. Normal renal function, high TmP/GFR, nonsuppressed calcitriol, and the characteristic FGF23 assay/genetic pattern distinguish HFTC. HFTC-associated hyperostosis can closely mimic osteomyelitis clinically and on MRI. (ito2021congenitalhyperphosphatemicconditions pages 3-4, alghubishi2024type1hyperphosphatemic pages 5-5)

11. Outcome and prognosis

Life expectancy, disease-specific mortality, and five- or ten-year survival have not been quantified. Many patients survive into adulthood, but morbidity can be profound. Major outcomes include chronic pain, impaired mobility, joint destruction, ulceration, secondary infection, disfiguring masses, repeated operations, dental complications, and possible vascular or visceral injury. (ramnitz2016phenotypicandgenotypic pages 13-17)

Prognostic factors are incompletely established. Persistent phosphate elevation, high calcium-phosphate product, extensive baseline lesion burden, poor adherence, and systemic inflammation are clinically concerning, but no validated prognostic model exists. Genotype does not reliably predict severity, and substantial intrafamilial variability argues for other modifiers. Long-term multidisciplinary surveillance should include function, skin integrity, inflammation, dental health, renal function, and individualized cardiovascular assessment.

12. Treatment

No FDA/EMA-approved disease-specific therapy or consensus algorithm exists. Expert management seeks to lower phosphate/calcium-phosphate product, suppress inflammatory complications, preserve function, and avoid surgical morbidity. The 2020 authoritative review concluded that efficacy evidence was limited to case reports and small cohorts and that no clearly effective therapy had been identified; this remains broadly consistent with the 2024 systematic-review evidence base. (ramnitz2016phenotypicandgenotypic pages 1-6, cherian2024clinicalcharacteristicstherapeutic pages 2-3)

Phosphate-directed treatment

• Low-phosphate diet: often 400–900 mg/day in the NIH cohort, ideally planned by a metabolic dietitian to avoid malnutrition.
• Sevelamer: non-calcium intestinal phosphate binder; avoid calcium-containing binders when possible because they may increase calcium-phosphate substrate.
• Aluminum hydroxide: effective binder but unsuitable for prolonged indiscriminate use because of aluminum toxicity; used in two NIH subjects.
• Acetazolamide: carbonic-anhydrase inhibitor inducing bicarbonaturia and phosphaturia. Monitor bicarbonate, potassium, renal function, and nephrolithiasis risk; metabolic acidosis is a recognized concern.
• Probenecid: promotes phosphaturia but has important drug interactions, including increased exposure to penicillins, cephalosporins, and trimethoprim-sulfamethoxazole.
• Nicotinamide: did not add clear benefit in the NIH cohort. (ramnitz2016phenotypicandgenotypic pages 13-17, ramnitz2016phenotypicandgenotypic pages 6-10)

Responses are inconsistent. In the NIH cohort, one mass completely resolved after 13 months of combined medical treatment, but individualized regimens, adherence differences, referral bias, and short follow-up preclude response-rate estimates. (ramnitz2016phenotypicandgenotypic pages 1-6)

Anti-inflammatory therapy

NSAIDs may treat mild attacks. For severe systemic inflammation, anakinra or canakinumab has reduced CRP and improved constitutional symptoms in isolated patients. In two NIH subjects, IL-1 blockade lowered inflammatory markers; one had resolution of calcinosis cutis and surrounding inflammation, and both reported improved energy, appetite, and well-being. These agents treat downstream inflammation and do not restore FGF23 activity. (ramnitz2016phenotypicandgenotypic pages 13-17, ramnitz2016phenotypicandgenotypic pages 1-6)

Surgery and supportive care

Complete excision may be considered for severe pain, ulceration, recurrent infection, neurovascular compromise, or major functional restriction. Surgery is a last resort because persistent hyperphosphatemia, incomplete excision, wound complications, and recurrence are common concerns. Physical/occupational therapy, wound care, analgesia, dental surveillance, and psychosocial support are appropriate.

Suggested NCIt intervention concepts are dietary therapy, phosphate-binding agent therapy, carbonic-anhydrase inhibition, anakinra, canakinumab, IL-1 inhibition, analgesic therapy, physical therapy, wound care, and surgical excision; exact NCIt codes should be validated before database loading.

Advanced and experimental therapy

Recombinant or long-acting FGF23 replacement is mechanistically attractive for GALNT3/FGF23 deficiency but remains experimental. Gene replacement, CRISPR editing, RNA therapy, and cell therapy have no established human implementation. Burosumab is an anti-FGF23 antibody and is mechanistically inappropriate—and potentially hazardous—in an FGF23-deficient/resistant hyperphosphatemic disorder. No disease-specific interventional ClinicalTrials.gov study was identified. The broad NIH observational natural-history protocol NCT00024804 includes bone/mineral disorders but is not an HFTC treatment trial.

13. Prevention

Primary prevention of a recessive genotype is limited to informed reproductive choice. Genetic counseling should address parental carrier testing, cascade testing, prenatal diagnosis, and preimplantation genetic testing when familial pathogenic variants are known. There is no vaccine, infectious prophylaxis, or population-screening program.

Secondary prevention consists of early recognition in siblings and relatives using serum phosphate, renal phosphate handling, and targeted genetic testing. Dental-root changes may appear early and have high penetrance, making dental radiographs a useful diagnostic clue. (lee2021across‐sectionalcohort pages 4-5)

Tertiary prevention includes dietary/pharmacological phosphate control, monitoring calcium-phosphate product and bicarbonate, avoiding unnecessary calcium/phosphate supplements, prompt treatment of inflammation or ulcer infection, dental care, skin protection, and minimizing repetitive pressure over lesions. Evidence that these measures prevent all calcification remains observational.

14. Other species and natural disease

No well-established naturally occurring veterinary counterpart was identified in the retrieved literature. The pathway is evolutionarily conserved across mammals, but veterinary “tumoral calcinosis” can have different etiologies and should not automatically be annotated as orthologous HFTC. The disorder is not infectious, transmissible, or zoonotic.

Relevant orthologs are Galnt3, Fgf23, and Kl in Mus musculus (NCBI Taxonomy 10090). Exact NCBI Gene IDs and any OMIA/VBO entries should be verified directly before knowledge-base ingestion.

15. Model organisms

Mouse models

• Galnt3-knockout mouse: reproduces low circulating intact Fgf23 and hyperphosphatemia despite increased bone Fgf23 expression. Circulating intact Fgf23 was approximately half that of controls, with increased C-terminal fragments. Mice did not consistently develop overt calcific masses, limiting fidelity to severe human HFTC; sex-specific growth retardation, infertility, and increased bone density were also reported.
• Fgf23-null mouse: reproduces hyperphosphatemia, elevated calcitriol, and ectopic/vascular calcification and strongly supports the causal endocrine pathway.
• Klotho-deficient models: reproduce deficient FGF23 signaling and mineral abnormalities and have been used to evaluate calcification-modifying strategies, although their broader premature-aging phenotype limits direct clinical translation. (ramnitz2016phenotypicandgenotypic pages 13-17, farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4)

These are genetic mammalian knockout models useful for studying phosphate sensing, FGF23 processing, renal transport, calcification, and candidate therapies. No validated HFTC organoid, patient-iPSC platform, zebrafish model, or humanized model was identified.

Recent developments, 2023–2024

1. 2024 systematic review: Cherian et al., Calcified Tissue International 115:215–228, published July 2024, DOI 10.1007/s00223-024-01247-8, systematically assessed clinical characteristics, therapeutic approaches, and lesion outcomes. Its underlying literature remains dominated by case reports and case series rather than controlled trials. (cherian2024clinicalcharacteristicstherapeutic pages 2-3)
2. Very-late onset: Iwasaki, published online October 3, 2023, DOI 10.1530/edm-23-0071, described genetically diagnosed elderly-onset disease and argued that HFTC should remain in the differential for unexplained hyperphosphatemia or ectopic calcinosis even in older adults. (iwasaki2023elderlyonsetcalcinosisof pages 6-6)
3. Phenotypic and allelic expansion: 2024 reports described recurrent osteomyelitis-like presentations, a three-sibling family with homozygous GALNT3 c.1524+1G>A, and additional novel GALNT3 variants. These reports reinforce use of WES/WGS in atypical cases but do not alter the three-gene causal model. (alghubishi2024type1hyperphosphatemic pages 5-5)
4. Current expert interpretation: recent work emphasizes phenotype diversity, dental and vascular surveillance, inflammatory biology, and the inadequacy of current phosphate-lowering therapy. The major unmet needs are prospective natural-history data, standardized lesion imaging and outcomes, and FGF23-replacement therapy.

Exact supporting abstract quotations

Short quotations retained from accessible abstracts include:

• HFTC is described as a “rare and disabling disorder of fibroblast growth factor 23 (FGF23) deficiency or resistance,” and periarticular calcinosis as “the primary cause of disability.” (ramnitz2016phenotypicandgenotypic pages 1-6)
• The dental cohort concluded that its study “defines the spectrum and confirms the high penetrance of dental features in HFTC.” (lee2021across‐sectionalcohort pages 4-5)
• The Galnt3 model supplied in-vivo evidence that impaired Galnt3 causes “decreased circulating Fgf23 and hyperphosphatemia, despite increased Fgf23 expression.” (farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4)

Evidence limitations and knowledge-base cautions

HFTC literature is exceptionally sparse. Percentages from cohorts of 8–17 individuals should not be treated as population frequencies. Prevalence, incidence, sex ratio, penetrance percentages, mortality, life expectancy, carrier frequency, standardized quality-of-life effects, pharmacogenomics, validated biomarkers of progression, and treatment-response rates remain unknown. Most 2023–2024 publications are systematic reviews or single-family reports rather than prospective studies. Ontology terms marked “suggested” should undergo release-specific validation against HPO, GO, CL, UBERON, CHEBI, NCIt, and MONDO before production loading.

References

1. (ramnitz2016phenotypicandgenotypic pages 1-6): Mary Scott Ramnitz, Pravitt Gourh, Raphaela Goldbach-Mansky, Felasfa Wodajo, Shoji Ichikawa, Michael J Econs, Kenneth E White, Alfredo Molinolo, Marcus Y Chen, Theo Heller, Jaydira Del Rivero, Patricia Seo-Mayer, Bita Arabshahi, Malaka B Jackson, Sarah Hatab, Edward McCarthy, Lori C Guthrie, Beth A Brillante, Rachel I Gafni, and Michael T Collins. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome. Journal of Bone and Mineral Research, 31:1845-1854, Oct 2016. URL: https://doi.org/10.1002/jbmr.2870, doi:10.1002/jbmr.2870. This article has 109 citations and is from a highest quality peer-reviewed journal.

2. (ito2021congenitalhyperphosphatemicconditions pages 1-2): Nobuaki Ito and Seiji Fukumoto. Congenital hyperphosphatemic conditions caused by the deficient activity of fgf23. Calcified Tissue International, 108:104-115, Jan 2021. URL: https://doi.org/10.1007/s00223-020-00659-6, doi:10.1007/s00223-020-00659-6. This article has 29 citations and is from a peer-reviewed journal.

3. (OpenTargets Search: Hyperphosphatemic familial tumoral calcinosis-FGF23,GALNT3,KL): Open Targets Query (Hyperphosphatemic familial tumoral calcinosis-FGF23,GALNT3,KL, 9 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

4. (ito2021congenitalhyperphosphatemicconditions pages 2-3): Nobuaki Ito and Seiji Fukumoto. Congenital hyperphosphatemic conditions caused by the deficient activity of fgf23. Calcified Tissue International, 108:104-115, Jan 2021. URL: https://doi.org/10.1007/s00223-020-00659-6, doi:10.1007/s00223-020-00659-6. This article has 29 citations and is from a peer-reviewed journal.

5. (farrow2011miscellaneousnoninflammatorymusculoskeletal pages 3-4): Emily G. Farrow, Erik A. Imel, and Kenneth E. White. Miscellaneous non-inflammatory musculoskeletal conditions. hyperphosphatemic familial tumoral calcinosis (fgf23, galnt3 and αklotho). Best practice & research. Clinical rheumatology, 25 5:735-47, Oct 2011. URL: https://doi.org/10.1016/j.berh.2011.10.020, doi:10.1016/j.berh.2011.10.020. This article has 78 citations.

6. (ito2021congenitalhyperphosphatemicconditions pages 3-4): Nobuaki Ito and Seiji Fukumoto. Congenital hyperphosphatemic conditions caused by the deficient activity of fgf23. Calcified Tissue International, 108:104-115, Jan 2021. URL: https://doi.org/10.1007/s00223-020-00659-6, doi:10.1007/s00223-020-00659-6. This article has 29 citations and is from a peer-reviewed journal.

7. (ramnitz2016phenotypicandgenotypic pages 6-10): Mary Scott Ramnitz, Pravitt Gourh, Raphaela Goldbach-Mansky, Felasfa Wodajo, Shoji Ichikawa, Michael J Econs, Kenneth E White, Alfredo Molinolo, Marcus Y Chen, Theo Heller, Jaydira Del Rivero, Patricia Seo-Mayer, Bita Arabshahi, Malaka B Jackson, Sarah Hatab, Edward McCarthy, Lori C Guthrie, Beth A Brillante, Rachel I Gafni, and Michael T Collins. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome. Journal of Bone and Mineral Research, 31:1845-1854, Oct 2016. URL: https://doi.org/10.1002/jbmr.2870, doi:10.1002/jbmr.2870. This article has 109 citations and is from a highest quality peer-reviewed journal.

8. (cherian2024clinicalcharacteristicstherapeutic pages 2-3): Kripa Elizabeth Cherian, Jacob Cherian, Dharmasivam Vinodhini, and Thomas Vizhalil Paul. Clinical characteristics, therapeutic options, and outcomes in hyperphosphatemic tumoral calcinosis: a systematic review. Calcified tissue international, 115:215-228, Jul 2024. URL: https://doi.org/10.1007/s00223-024-01247-8, doi:10.1007/s00223-024-01247-8. This article has 6 citations and is from a peer-reviewed journal.

9. (ramnitz2016phenotypicandgenotypic pages 13-17): Mary Scott Ramnitz, Pravitt Gourh, Raphaela Goldbach-Mansky, Felasfa Wodajo, Shoji Ichikawa, Michael J Econs, Kenneth E White, Alfredo Molinolo, Marcus Y Chen, Theo Heller, Jaydira Del Rivero, Patricia Seo-Mayer, Bita Arabshahi, Malaka B Jackson, Sarah Hatab, Edward McCarthy, Lori C Guthrie, Beth A Brillante, Rachel I Gafni, and Michael T Collins. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome. Journal of Bone and Mineral Research, 31:1845-1854, Oct 2016. URL: https://doi.org/10.1002/jbmr.2870, doi:10.1002/jbmr.2870. This article has 109 citations and is from a highest quality peer-reviewed journal.

10. (lee2021across‐sectionalcohort pages 4-5): Alisa E Lee, Emily Y Chu, Pamela J Gardner, Olivier Duverger, Amanda Saikali, Sean K Wang, Rachel I Gafni, Iris R Hartley, Kelly G Ten Hagen, Martha J Somerman, and Michael T Collins. A cross‐sectional cohort study of the effects of fgf23 deficiency and hyperphosphatemia on dental structures in hyperphosphatemic familial tumoral calcinosis. JBMR Plus, Mar 2021. URL: https://doi.org/10.1002/jbm4.10470, doi:10.1002/jbm4.10470. This article has 18 citations and is from a peer-reviewed journal.

11. (chakhtoura2018hyperphosphatemicfamilialtumoral pages 1-2): M. Chakhtoura, M.S. Ramnitz, N. Khoury, G. Nemer, N. Shabb, A. Abchee, A. Berberi, M. Hourani, M. Collins, S. Ichikawa, and G. El Hajj Fuleihan. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (fgf23) mutation: a report of two affected families and review of the literature. Osteoporosis International, 29:1987-2009, Jun 2018. URL: https://doi.org/10.1007/s00198-018-4574-x, doi:10.1007/s00198-018-4574-x. This article has 22 citations and is from a domain leading peer-reviewed journal.

12. (iwasaki2023elderlyonsetcalcinosisof pages 6-6): Hiroaki Iwasaki. Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma. Endocrinology, Diabetes & Metabolism Case Reports, Oct 2023. URL: https://doi.org/10.1530/edm-23-0071, doi:10.1530/edm-23-0071. This article has 1 citations and is from a peer-reviewed journal.

13. (alghubishi2024type1hyperphosphatemic pages 5-5): Somayah A Alghubishi, Eman J Ghazwani, Sami E Abdelmogeit, and Khalid Alzubair. Type 1 hyperphosphatemic familial tumoral calcinosis associated with a homozygous variant mutation in the galnt3 gene. Oct 2024. URL: https://doi.org/10.7759/cureus.71390, doi:10.7759/cureus.71390. This article has 0 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0002905 (2 mentions) - the report calls it "Universal biochemical hallmark in characterized cohorts; persistent, age-adjusted elevation"; HP calls it Hyperphosphatemia

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: Orphanet, OMIM, Taxonomy.